Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence

Sponsor
Weill Cornell Medical College in Qatar
Study ID
NCT07515807
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Coronary Syndromes (ACS)
  • Artifical Intelligence
  • Cardio Vascular Disease
  • Pre Diabetes
  • Type 2 Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.

Key Dates

First listed
Apr 7, 2026
Start date
Jul 16, 2026
Status verified
Mar 2026
Primary completion
Jul 16, 2030
Completion
Jul 16, 2030

Study Design

Enrollment
10,000 participants (estimated)

Primary Outcome Measure

Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients [ Time Frame: 5 years ]

Central Contacts

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies